Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Nov-2017

No. of Pages : 164

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2011 to YTD 2017 14
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Two Equine Health Products from Bayer HealthCare 22
Merial to Acquire Manufacturing Facility from Merck 23
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 24
Boehringer Ingelheim Plans To Acquire OTC Brands In India 26
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 27
Boehringer Ingelheim Acquires Fremont Facility From Amgen 28
Partnerships 30
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 30
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 31
Geisinger Enters into Agreement with Boehringer Ingelheim 32
Boehringer Ingelheim Enters into Partnership with Peking University 33
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 34
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 35
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 36
Boehringer Ingelheim Enters into Agreement with Esteve 37
leadXpro to Enter into Agreement with Boehringer Ingelheim 38
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 39
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 40
Boehringer Ingelheim Enters into Research Agreement with Saniona 41
Boehringer Ingelheim and University of Dundee Enter into Agreement 42
Eli Lilly Enters into Agreement with Boehringer Ingelheim 43
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 44
Boehringer Ingelheim Enters into Research Agreement with BioMed X 45
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 46
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 47
Boehringer May Enter into Agreement with AbbVie 48
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 49
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 50
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 51
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 53
Boehringer Ingelheim and Philogen Enter into Partnership 54
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 55
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 57
Boehringer Ingelheim Extends Research Agreement with BioMed X 58
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 59
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 61
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 62
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 63
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 64
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 65
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 66
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 67
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 68
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 69
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 70
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 71
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 72
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim 73
Pfenex Enters Into Collaboration With Boehringer Ingelheim 74
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 75
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 76
Licensing Agreements 78
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 78
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 79
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 80
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 81
Zealand Pharma Enters into Licensing Agreement with Boehringer 82
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 83
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 84
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 85
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 86
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 87
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 89
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 90
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 92
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 93
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 94
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 95
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology 96
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 97
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 98
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim 99
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim 101
Centegen Enters Into Licensing Agreement With Merial For CEN-102 102
Asset Transactions 103
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 103
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 104
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 105
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 106
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 107
Acquisition 108
Boehringer Ingelheim May Sell Roxane Labs 108
Boehringer Ingelheim GmbH - Key Competitors 109
Boehringer Ingelheim GmbH - Key Employees 110
Boehringer Ingelheim GmbH - Locations And Subsidiaries 111
Head Office 111
Other Locations & Subsidiaries 111
Recent Developments 113
Financial Announcements 113
Aug 02, 2017: Boehringer Ingelheim Achieves Good Growth in the First Half of 2017 113
Apr 05, 2017: Successful financial year 2016 for Boehringer Ingelheim 114
Corporate Communications 115
Jun 10, 2016: Simone Menne - new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance 115
Government and Public Interest 116
Jul 04, 2016: Gaia Novarino wins Boehringer Ingelheim's FENS Award 2016 for Exceptional Research in Neuroscience 116
Feb 10, 2016: The European Society of Cardiology announces winners of innovative cardiovascular research grant programme 117
Product News 118
12/21/2016: European Medicines Agency: Clinical data for Praxbind now available online 118
12/12/2016: U.S. FDA approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes 119
12/02/2016: FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes 120
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 121
09/08/2016: New analysis showed dose adjustment of Gilotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer 123
08/15/2016: Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind (idarucizumab) Usage in Clinical Practice 124
Jun 21, 2017: New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients 126
06/13/2016: New first-line treatment for lung cancer now funded by Quebec public drug plan (RAMQ) 127
06/11/2016: New Study Results Show Tradjenta (Linagliptin) Reduces Blood Sugar In Adults With Type 2 Diabetes At Risk For Kidney Impairment 128
May 23, 2016: Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing 129
05/15/2017: Pharmaxis Drug Discovery Set To Generate Further 10M Milestone Payment In 2017 As Boehringer Confirms Second Clinical Study 130
04/04/2016: Precision medicine brings new hope to those with advanced urothelial cancer 131
03/08/2016: Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals 133
02/19/2016: New drug reverses the effects of blood thinner in patients with brain hemorrhage 134
02/17/2016: Praxbind(idarucizumab) reimbursed in England, Ireland and Wales 135
01/11/2016: NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies 136
Product Approvals 137
May 16, 2016: Praxbind (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa (dabigatran etexilate) Now Approved in Canada With Conditions 137
Apr 15, 2016: FDA approves Gilotrif (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung 138
Apr 07, 2016: Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung 139
Mar 29, 2016: FDA Approves Supplemental New Drug Application for Boehringer Ingelheim's STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life 140
Feb 29, 2016: European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung 141
Clinical Trials 142
Aug 24, 2017: Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH 142
Nov 15, 2016: Updated Phase III Results Reinforce Safety and Efficacy of Praxbind (idarucizumab) in Urgent Situations 143
Oct 18, 2016: Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia 144
Sep 05, 2016: New Data: Spiolto Respimat significantly improves exercise capacity in people with COPD 145
Jul 25, 2016: Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials following pre-planned analysis from independent Data Monitoring Committee 146
May 09, 2016: The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer 147
Apr 13, 2016: Head-to-head study demonstrating Gilotrif (afatinib) significantly improved clinical outcomes compared to Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology 149
Apr 02, 2016: Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) in Emergency Situations 151
Feb 09, 2016: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures 153
Jan 27, 2016: Boehringer Ingelheim's Giotrif / Gilotrif (afatinib) demonstrated superiority to Iressa (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer 155
Jan 25, 2016: Afatinib shows clinical benefit for lung cancer patients with brain metastases 157
Other Significant Developments 158
Nov 20, 2017: Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential 158
Jul 31, 2017: Boehringer Ingelheim And Lilly To Support New American College Of Cardiology Program To Highlight The Increasingly Important Role Of Cardiologists In Reducing Cardiovascular Risk 159
Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 160
Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million 161
Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 162
Jul 20, 2016: The European Stroke Organisation and Boehringer Ingelheim launch the "Angels Initiative", a unique healthcare initiative to improve acute stroke care across Europe 163
Appendix 164
Methodology 164
About GlobalData 164
Contact Us 164
Disclaimer 164

List of Tables
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Boehringer Ingelheim GmbH, Deals By Therapy Area, 2011 to YTD 2017 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2011 to YTD 2017 14
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Two Equine Health Products from Bayer HealthCare 22
Merial to Acquire Manufacturing Facility from Merck 23
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 24
Boehringer Ingelheim Plans To Acquire OTC Brands In India 26
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 27
Boehringer Ingelheim Acquires Fremont Facility From Amgen 28
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 30
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 31
Geisinger Enters into Agreement with Boehringer Ingelheim 32
Boehringer Ingelheim Enters into Partnership with Peking University 33
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 34
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 35
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 36
Boehringer Ingelheim Enters into Agreement with Esteve 37
leadXpro to Enter into Agreement with Boehringer Ingelheim 38
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 39
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 40
Boehringer Ingelheim Enters into Research Agreement with Saniona 41
Boehringer Ingelheim and University of Dundee Enter into Agreement 42
Eli Lilly Enters into Agreement with Boehringer Ingelheim 43
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 44
Boehringer Ingelheim Enters into Research Agreement with BioMed X 45
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 46
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 47
Boehringer May Enter into Agreement with AbbVie 48
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 49
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 50
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 51
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 53
Boehringer Ingelheim and Philogen Enter into Partnership 54
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 55
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 57
Boehringer Ingelheim Extends Research Agreement with BioMed X 58
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 59
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 61
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 62
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 63
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 64
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 65
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 66
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 67
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 68
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 69
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 70
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 71
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 72
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim 73
Pfenex Enters Into Collaboration With Boehringer Ingelheim 74
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 75
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 76
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 78
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 79
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 80
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 81
Zealand Pharma Enters into Licensing Agreement with Boehringer 82
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 83
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 84
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 85
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 86
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 87
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 89
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 90
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 92
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 93
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 94
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 95
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology 96
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 97
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 98
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim 99
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim 101
Centegen Enters Into Licensing Agreement With Merial For CEN-102 102
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 103
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 104
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 105
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 106
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 107
Boehringer Ingelheim May Sell Roxane Labs 108
Boehringer Ingelheim GmbH, Key Competitors 109
Boehringer Ingelheim GmbH, Key Employees 110
Boehringer Ingelheim GmbH, Other Locations 111
Boehringer Ingelheim GmbH, Subsidiaries 111

List of Figures
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2011 to YTD 2017 14

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027